drugset / Trial / NCT00637780

Study To Determine The Pharmacokinetics Of Sulfasalazine In Children With Juvenile Idiopathic Arthritis

NCT00637780

Phase 4 Terminated 2 enrolled Pfizer
NaSingle-groupOpen-labelTreatment

Summary

This study will characterize the steady state pharmacokinetics of sulfasalazine delayed release tablets in pediatric Juvenile Idiopathic Arthritis patients. Data from this study will fulfill the post approval commitment to the FDA.

Timeline

Start
2010-06
Primary completion
2014-01
Completion
2014-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Sulfasalazine Small molecule 30 mg/kg
Subject Sulfasalazine Small molecule 60 mg/kg